Premium
1α‐HYDROXYVITAMIN D 3 IN THE LONG‐TERM MANAGEMENT OF H YPOP A R ATH Y ROIDISM AND PSEUDOHYPOPARATHYROIDISM
Author(s) -
LEWIN I. G.,
PAPAPOULOS S. E.,
O'RIORDAN J. L. H.
Publication year - 1977
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1977.tb03382.x
Subject(s) - pseudohypoparathyroidism , medicine , endocrinology , phos , term (time) , chemistry , parathyroid hormone , calcium , physics , biochemistry , quantum mechanics
SUMMARY Normocalcaemia was restored and maintained in eleven hypoparathyroid and two pseudohypoparathyroid patients treated for up to 36 months with 1α‐hydroxy‐vitamin D 3 . It was found to be a potent compound, maintenance doses rangmg from 4μg weekly to 2μg daily. Supplementary oral calcium was used in acutely and profoundly hypocalcaemic patients but was given to only two patients as part of long‐term therapy. Hypercalcaemic episodes occurring during treatment were of short duration and could be controlled by withdrawal of medication alone.